NFKB1 and ovarian carcinoma: In the research of ovarian cancer, targeting microRNA1301 can inhibit the proliferation of cisplatin-resistant ovarian cancer cells by inhibiting the NF-κB signaling pathway and regulating autophagy, thus playing a defensive role in the occurrence and development of drug-resistant ovarian cancer cells [111].